Comparative efficacy and effectiveness: An opportunity for clinical pharmacology

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 6, 2011, Pages 761-763

  Lalonde, R L ^a   Willke, R J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; FONDAPARINUX; GENERIC DRUG; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

CLINICAL PHARMACOLOGY; COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG FORMULATION; DRUG MARKETING; HEALTH CARE; HUMAN; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; UNITED STATES; VENOUS THROMBOEMBOLISM;

COMPARATIVE EFFECTIVENESS RESEARCH; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUGS, GENERIC; HEALTH CARE COSTS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PHARMACOLOGY, CLINICAL; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 81355135511     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.240     Document Type: Review

References (11)

1. Honig, P.K. Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology. Clin. Pharmacol. Ther. 89, 151-156 (2011).
2. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004). (Pubitemid 39173511)
3. Elias, T., Gordian, M., Singh, N. & Zemmel, R. Why products fail in phase III. In Vivo 4, 49-54 (2006).
4. Arrowsmith, J. Phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10, 82 (2011).
5. Paul, S.M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
6. O'Donnell, J.C, Pham, S.V., Pashos, C.L., Miller, D.W. & Smith, M.D. Health technology assessment: lessons learned from around the world-an overview. Value in Health 12 (suppl. 2), S1-S5 (2009).
7. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 〈http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf〉 (June 2008).
8. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007). (Pubitemid 46950619)
9. Caldwell, D.M., Ades, A.E. & Higgins, J.P.T. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331, 897-900 (2005). (Pubitemid 41502718)
10. Mandema, J.W., Boyd, R.A. & DiCarlo, L.A. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis. Clin. Pharmacol. Ther. 90, 820-827 (2011).
11. European Union, European Commission, Pharmaceutical Forum. Data availability to conduct [on] relative effectiveness assessments 〈http://ec.europa.eu/pharmaforum/docs/rea-data-en.pdf〉 (2007).